{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:59:12Z","timestamp":1779382752923,"version":"3.53.1"},"reference-count":31,"publisher":"e-Century Publishing Corporation","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/ydkm2312","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T05:01:56Z","timestamp":1722315716000},"page":"3395-3404","source":"Crossref","is-referenced-by-count":2,"title":["Effects of tibolone combined with zoledronic acid on bone density, bone metabolism, and pain in postmenopausal patients with osteoporosis"],"prefix":"10.62347","volume":"16","author":[{"given":"San-Bao","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1517\/14656566.2016.1124856","article-title":"Management of severe osteoporosis","volume":"17","author":"Miller","year":"2016","unstructured":"Miller PD. Management of severe osteoporosis. Expert Opin Pharmacother 2016; 17: 473-488.","journal-title":"Expert Opin Pharmacother"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00198-021-06291-w","article-title":"Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study","volume":"33","author":"Lai","year":"2022","unstructured":"Lai EC, Lin TC, Lange JL, Chen L, Wong ICK, Sing CW, Cheung CL, Shao SC and Yang YK. Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study. Osteoporos Int 2022; 33: 1155-1164.","journal-title":"Osteoporos Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2147\/CIA.S54614","article-title":"The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil","volume":"10","author":"Baccaro","year":"2015","unstructured":"Baccaro LF, Conde DM, Costa-Paiva L and Pinto-Neto AM. The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Clin Interv Aging 2015; 10: 583-591.","journal-title":"Clin Interv Aging"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","article-title":"Use of bone turnover markers in postmenopausal osteoporosis","volume":"5","author":"Eastell","year":"2017","unstructured":"Eastell R and Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol 2017; 5: 908-923.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"100796","DOI":"10.1016\/j.ijotn.2020.100796","article-title":"Effect of exercise on bone mineral density and quality of life among postmenopausal women with osteoporosis without fracture: a systematic review","volume":"39","author":"Anupama","year":"2020","unstructured":"Anupama DS, Norohna JA, Acharya KK, Ravishankar and George A. Effect of exercise on bone mineral density and quality of life among postmenopausal women with osteoporosis without fracture: a systematic review. Int J Orthop Trauma Nurs 2020; 39: 100796.","journal-title":"Int J Orthop Trauma Nurs"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006; 13: 340-369; quiz 368-9.","DOI":"10.1097\/01.gme.0000222475.93345.b3"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3803\/EnM.2021.301","article-title":"Long-term treatment of postmenopausal osteoporosis","volume":"36","author":"Brown","year":"2021","unstructured":"Brown JP. Long-term treatment of postmenopausal osteoporosis. Endocrinol Metab (Seoul) 2021; 36: 544-552.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.maturitas.2007.02.008","article-title":"Tibolone for prevention and treatment of postmenopausal osteoporosis","volume":"57","author":"Ettinger","year":"2007","unstructured":"Ettinger B. Tibolone for prevention and treatment of postmenopausal osteoporosis. Maturitas 2007; 57: 35-38.","journal-title":"Maturitas"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH and Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab 2019; 104: 1595-1622.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Duralde ER, Sobel TH and Manson JE. Management of perimenopausal and menopausal symptoms. BMJ 2023; 382: e072612.","DOI":"10.1136\/bmj-2022-072612"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"DM","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF and Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB and Cummings SR. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 2016; 101: 3163-3170.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Liao RX, Yu M, Jiang Y and Xia W. Management of osteoporosis with calcitriol in elderly Chinese patients: a systematic review. Clin Interv Aging 2014; 9: 515-526.","DOI":"10.2147\/CIA.S40465"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.12669\/pjms.36.7.1964","article-title":"Clinical effect of zoledronic acid in the treatment of senile osteoporosis","volume":"36","author":"Kong","year":"2020","unstructured":"Kong L, Zuo K and Ma L. Clinical effect of zoledronic acid in the treatment of senile osteoporosis. Pak J Med Sci 2020; 36: 1703-1707.","journal-title":"Pak J Med Sci"},{"key":"ref14","unstructured":"Shi N, Zhao C, Fang C, Zhang D, Zhou Z and Ouyang G. Effects of acupoint catgut embedding on the postmenopausal osteoporosis patients and related mechanism. Am J Transl Res 2021; 13: 1789-1798."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4055\/cios.2012.4.4.307","article-title":"Retrograde intramedullary nailing for distal femur fracture with osteoporosis","volume":"4","author":"Kim","year":"2012","unstructured":"Kim J, Kang SB, Nam K, Rhee SH, Won JW and Han HS. Retrograde intramedullary nailing for distal femur fracture with osteoporosis. Clin Orthop Surg 2012; 4: 307-312.","journal-title":"Clin Orthop Surg"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.biopha.2018.08.018","article-title":"Postmenopausal osteoporosis and breast cancer: the biochemical links and beneficial effects of functional foods","volume":"107","author":"Muhammad","year":"2018","unstructured":"Muhammad A, Mada SB, Malami I, Forcados GE, Erukainure OL, Sani H and Abubakar IB. Postmenopausal osteoporosis and breast cancer: the biochemical links and beneficial effects of functional foods. Biomed Pharmacother 2018; 107: 571-582.","journal-title":"Biomed Pharmacother"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ and Watts NB. American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 2020; 26 Suppl 1: 1-46.","DOI":"10.4158\/GL-2020-0524SUPPL"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1002\/jcb.26550","article-title":"A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis","volume":"119","author":"Liu","year":"2018","unstructured":"Liu GF, Wang ZQ, Liu L, Zhang BT, Miao YY and Yu SN. A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis. J Cell Biochem 2018; 119: 4469-4481.","journal-title":"J Cell Biochem"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, Marata AM, Magrini N, D’Amico R, Bassi C and Maestri E. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev 2016; 10: CD008536.","DOI":"10.1002\/14651858.CD008536.pub3"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.tem.2020.04.007","article-title":"Tibolone as hormonal therapy and neuroprotective agent","volume":"31","author":"R&#xED","year":"2020","unstructured":"Del Río JP, Molina S, Hidalgo-Lanussa O, Garcia-Segura LM and Barreto GE. Tibolone as hormonal therapy and neuroprotective agent. Trends Endocrinol Metab 2020; 31: 742-759.","journal-title":"Trends Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E and Seaman J. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19: 558-567.","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.beem.2018.09.005","article-title":"Postmenopausal osteoporosis: assessment and management","volume":"32","author":"Rizzoli","year":"2018","unstructured":"Rizzoli R. Postmenopausal osteoporosis: assessment and management. Best Pract Res Clin Endocrinol Metab 2018; 32: 739-757.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017; 24: 728-753.","DOI":"10.1097\/GME.0000000000000921"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4137\/cmwh.s10483","article-title":"Abnormal bleeding during menopause hormone therapy: insights for clinical management","volume":"6","author":"Medeiros SF","year":"2013","unstructured":"de Medeiros SF, Yamamoto MM and Barbosa JS. Abnormal bleeding during menopause hormone therapy: insights for clinical management. Clin Med Insights Womens Health 2013; 6: 13-24.","journal-title":"Clin Med Insights Womens Health"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.5603\/MRJ.a2021.0014","article-title":"Tibolone among drugs in the therapy of postmenopausal women","volume":"6","author":"Nieciecka","year":"2021","unstructured":"Nieciecka A, Kędziora-Kornatowska K and Janiszewska M. Tibolone among drugs in the therapy of postmenopausal women. Med Res J 2021; 6: 140-146.","journal-title":"Med Res J"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Castrejón-Delgado L, Castelán-Martínez OD, Clark P, Garduño-Espinosa J, Mendoza-Núñez VM and Sánchez-Rodríguez MA. Effect of tibolone on bone mineral density in postmenopausal women: systematic review and meta-analysis. Biology (Basel) 2021; 10: 211.","DOI":"10.3390\/biology10030211"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1515\/dmpt-2020-0187","article-title":"Effect of zoledronic acid on bone nanocomposites organization and prevention of bone mineral density loss in ovariectomized rats","volume":"36","author":"Kostyshyn","year":"2021","unstructured":"Kostyshyn NM, Gzhegotskyi MR, Kostyshyn LP and Mudry SI. Effect of zoledronic acid on bone nanocomposites organization and prevention of bone mineral density loss in ovariectomized rats. Drug Metab Pers Ther 2021; 36: 239-245.","journal-title":"Drug Metab Pers Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jbmr.292","article-title":"Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial","volume":"26","author":"JA","year":"2011","unstructured":"Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P and Reid IR; HORIZON Pivotal Fracture Group. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. J Bone Miner Res 2011; 26: 984-992.","journal-title":"J Bone Miner Res"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Lien YTK, Madrasi K, Samant S, Kim MJ, Li F, Li L, Wang Y and Schmidt S. Establishment of a disease-drug trial model for postmenopausal osteoporosis: a zoledronic acid case study. J Clin Pharmacol 2020; 60 Suppl 2: S86-S102.","DOI":"10.1002\/jcph.1748"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1359\/jbmr.070906","article-title":"Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure","volume":"23","author":"RR","year":"2008","unstructured":"Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J and Eriksen EF. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008; 23: 6-16.","journal-title":"J Bone Miner Res"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/7\/ajtr0157104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:54:25Z","timestamp":1766022865000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/7\/ajtr0157104.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/ydkm2312","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}